It’s only fair to share… Epsametostat CAS 2202678-06-4 MF C31H36F3N7O3 MW611.7 g/mol N-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-6-methyl-1-(6-methylpyridazin-3-yl)-5-{(1R)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethyl}indolizine-7-carboxamide N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-6-methyl-1-(6-methylpyridazin-3-yl)-5-[(1R)-1-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]ethyl]indolizine-7-carboxamidehistone N-methyltransferase inhibitor, antineoplastic, Shanghai Haihe Pharmaceutical, HH 2853, (R)-HH2853 Epsametostat is an investigational new drug that is being evaluated for the treatment of peripheral T-cell lymphoma. It is a EZH1/EZH2 inhibitor developed by Shanghai Haihe Pharmaceutical Research & Development Co., Ltd.[1][2][3] PAT PAT https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018045971&_cid=P22-MGK809-27208-1 AS ON JUNE2025 4.45 …